, a deletion variant conferring clinically relevant FDC resistance via enhanced interaction and compromised inhibition. Its localization on a highly transmissible plasmid with a dual-copy architecture underscores its potential for rapid dissemination. Continuous genomic surveillance of emerging KPC variants is critical to preserving the clinical utility of FDC.
Y et al. (Wed,) studied this question.